FIVE TRENDS SHAPING THE FUTURE OF THE INTERVENTIONAL CARDIOLOGY AND PERIPHERAL VASCULAR DEVICE MARKET

The interventional cardiology and peripheral vascular device market is growing and gaining traction due to rapid growth of the geriatric population and the associated increase in the prevalence of coronary artery disease and peripheral vascular disease. Some of the key trends in the interventional cardiology and peripheral vascular device market are rising adoption of
Five Trends Shaping the Future of the Interventional Cardiology and Peripheral Vascular Device Market, December 2021

transcatheter aortic valve replacement procedures and transcatheter mitral valve repair, growing use of bioresorbable stents, and adoption of drug-eluting balloons cardiac catheterization. The major growth drivers for this market are the growing elderly population, a rise in the prevalence of chronic diseases, advancements in medical technology and research, improvement of healthcare infrastructure in developing countries, and change in lifestyles.
The interventional cardiology and peripheral vascular device market is divided into several segments, such as angioplasty balloons, angioplasty stents, angioplasty catheters, EVAR stent grafts, IVC filters, embolic protection devices, guidewires, arteriotomy closure devices, intravascular ultrasound systems (IVUS), and synthetic surgical grafts. Key players in the interventional cardiology and peripheral vascular device market include Medtronic plc, Boston Scientific, Abbott Laboratories, Terumo, and C.R. Bard. These have been working on different strategies to drive sales using highly influential marketing approaches; however, as we examine the challenges and opportunities ahead in this market, companies can benefit from a strategy of developing transcatheter aortic valve replacement (TAVR) procedures and transcatheter mitral valve repair (TMVR) technology, along with the key target market trends we have identified. Lucintel predicts the global interventional cardiology and peripheral vascular device market will be valued at $29.9 billion by 2025, with an expected CAGR of approx. 4.7% between 2020 and 2025.

Lucintel identifies five trends set to influence the global interventional cardiology and peripheral vascular device market. Most of the industry players and experts agree that these five trends will accelerate developments in the interventional cardiology and peripheral vascular device industry in the near future. In terms of the widespread knowledge about the interventional cardiology and peripheral vascular device market already on the horizon, there is still a lack of unified perspective on the direction the industry is moving to proactively address developments. To help bring more clarity to this gap, our study aims to provide insights concerning the direction that changes are taking and how these changes will impact the interventional cardiology and peripheral vascular device market.

1. Rising Adoption of Transcatheter Aortic Valve Replacement (TAVR) Procedures

Transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a thickened aortic valve that can’t fully open (aortic valve stenosis). The aortic valve is
located between the lower left heart chamber (left ventricle) and the body’s main artery (aorta). If the valve doesn’t open correctly, blood flow from the heart to the body is reduced. TAVR can help restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. This procedure is less painful, the risk of infection is lower, and recovery is quicker compared to open heart surgery. It is FDA-approved and has emerged as an innovative technology for people with symptomatic aortic stenosis who are considered high-risk patients for standard valve replacement surgery.

2. Transcatheter Mitral Valve Repair (TMVR)

Transcatheter mitral valve repair (TMVR) technologies are expanding rapidly. TMVR procedures have the potential to become alternatives to surgery for specific patients. TMVR devices can be differentiated according to the portion of the mitral valve they are intended to repair: the leaflet, the annulus, or the chordae, or a remodeling of the ventricles. The early results of TMVR technologies seem promising but long-term sustainability and effectiveness have not been determined. Yet, given the advancements in transcatheter technologies, it is conceivable that in the future, mitral regurgitation will mainly be treated using a minimally invasive approach.
3. Growing Use of Bioresorbable Stents

Bioresorbable stents (BRSs) are also referred to as bioabsorbable stents, bioresorbable scaffolds, and dissolving stents. The concept of a bioresorbable stent is to provide temporal support to the vessel before being degraded and resorbed by the body, promoting vessel healing and restoration of vasomotion. BRSs are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis or late-stent thrombosis, and they require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRSs avoid these issues by dissolving and disappearing from the vessel after around 2-4 years. This returns the vessel to its natural state and allows for the return of vasodilation and vasoconstriction. BRSs have had some issues in clinical trials with not aligning with the performance of standard metallic drug-eluting stents (DES) due to their thick stent struts. Newer-generation BRSs are in development and feature struts smaller than 100 micros, which will be closer to those of current generation metallic stents.

4. Adoption of Drug-Eluting Balloons

Drug-eluting balloons are conventional angioplasty balloons covered with an anti-restenosis drug which is released into the vessel wall during inflation of the balloon. Drug-eluting stents have high restenosis rates, which means that blockage in vessels can reoccur even after a successful operation. A new-
A generation drug-eluting balloon with a high delivery dose provides a solution to this ongoing problem and potentially overcomes high rates of restenosis in small vessels. Drug-eluting balloons are efficient medical devices for angioplasty procedures.

5. Cardiac Catheterization

Cardiac catheterization is a procedure in which a thin, flexible tube (catheter) is guided through a blood vessel to the heart to diagnose or treat certain heart conditions, such as clogged arteries or irregular heartbeats. Cardiac catheterization offers doctors important information about the heart muscle, heart valves, and blood vessels in the heart.

During cardiac catheterization, doctors can do different heart tests, deliver treatment, or remove a piece of heart tissue for examination. Some heart disease treatments such as coronary angioplasty and coronary stenting are done using cardiac catheterization. Recovery time for a cardiac catheterization is quick, and carry only a low risk of complications.

Strategic Considerations for Key Players in the Interventional Cardiology and Peripheral Vascular Device Market

The interventional cardiology and peripheral vascular device industry is dynamic and ever-changing. Successful industry players are necessarily masters of innovation, change, and adaptation. To retain this status, they need to be attentive to current trends. We believe there will be promising opportunities for interventional cardiology and peripheral vascular devices in hospitals and ambulatory surgical centers. As per Lucintel's latest market research report (Source: https://www.lucintel.com/interventional-cardiology-peripheral-vascular-devi.aspx), the interventional cardiology and peripheral vascular device market is expected to grow with a
CAGR of approx. 4.7% between 2020 and 2025, and reach $29.9 billion by 2025. This market is primarily driven by an increase of the elderly population, a rise in the prevalence of chronic diseases, advancements in medical technology and research, improvement of healthcare infrastructure in developing countries, and change in lifestyles.

Whether you are new to the interventional cardiology and peripheral vascular device market or an experienced player, it is important to understand the trends that impact the development process, as these trends as listed above will lead players to create long-term strategy formulation that will allow them to remain competitive and successful in the long run. For example, to capture growth, some of the strategic considerations for players in the interventional cardiology and peripheral vascular device market are as follows:

- Interventional cardiology and peripheral vascular device market players can increase their capabilities to develop coronary stents and PTCA balloons.
- Players can focus on transcatheter mitral valve repair technologies and aortic stent grafts, which are expected to lead future trends.
- Investment to increase competencies in the development of minimally invasive procedural devices such as heart-lung bypass machines
- Research and development activities for development of advanced bioresorbable stents
**Note:** In order to gain better understanding, and learn more about the scope, benefits, and companies researched, as well as other details in the interventional cardiology and peripheral vascular device market report from Lucintel, click on [https://www.lucintel.com/interventional cardiology and peripheral vascular device-market.aspx](https://www.lucintel.com/interventional cardiology and peripheral vascular device-market.aspx). This comprehensive report provides you in-depth analysis on market trends and forecast, segment analysis, regional analysis, competitive benchmarking, and company profiling of key players. In addition, we also offer **strategic growth consulting** to meet your customized needs. We have worked with many PE firms and corporate customers in the process of their market entry and M & A initiatives.
Lucintel - At a Glance

- Premier management consulting and market research firm. Founded in 1998.
- Deep global insights into major industries. Team of over 120 analysts/consultants across globe.
- Management comprised of PhDs, MBAs, and subject matter experts. Headquarter in Dallas, USA.

Conducted 500+ consulting projects across industries for 3M, Audi, Dupont, Carlyle, GE, etc.

Consulting Services
- Opportunity screening
- Market entry strategy
- Supply chain analysis
- Growth finance
- Strategic consulting
- Competitive assessment
- Due diligence
- M & A services

Why Lucintel
- Clients we serve: Over 1000 clients from 70 countries – Fortune 500 companies
- Strategic advice: Over 20 years of proven global strategic management consulting experience

Industries Served

Contact Us

Sanjay Mazumdar, Ph.D.
CEO, Author, & Strategist
Email: sanjay.mazumdar@Lucintel.com
Tel.: 972-636-5056

Eric Dahl
Senior Executive Advisor
Email: eric.dahl@Lucintel.com
Tel.: +1-323-388-6571

Brandon Fitzgerald
Director of Client Engagement
Email: brandon.fitzgerald@Lucintel.com
Tel.: +1-303-775-0751

Sabonn Dammarell
Client Engagement Specialist
Email: sabonn.dammarell@Lucintel.com
Tel.: +1-208-570-4101